疏肝解郁胶囊联合帕罗西汀治疗首发抑郁症效果观察

Effect observation of shuganjieyu capsule combined with paroxetine in treatment of first-episode depression

目的观察疏肝解郁胶囊联合帕罗西汀治疗首发抑郁症的效果及不良反应。方法将首发抑郁症患者60例随机分为观察组及对照组各30例。观察组采用疏肝解郁胶囊联合帕罗西汀治疗,对照组采用帕罗西汀治疗。对比2组治疗2、4、8周汉密尔顿抑郁量表(HAMD)评分和疗效及不良反应。结果治疗前2组HAMD评分比较差异无统计学意义(P>0.05)。治疗后,观察组HAMD评分在第2周开始下降,对照组HAMD评分在第4周末开始下降。第2、4、8周,2组间差异有统计学意义(P<0.05)。观察组治疗4、8周的痊愈率和显效率均高于对照组,差异有统计学意义(P<0.05)。2组不良反应发生率差异无统计学意义(P>0.05)。结论相对于单用帕罗西汀,疏肝解郁胶囊联合帕罗西汀治疗抑郁症起效快,临床治愈率高,且不良反应未见明显增加,值得临床进一步推广应用。

Objective To observe the efficacy and safety of shuganjieyu capsule combined with paroxetine in treatment of first-episode depression. Methods 60 first-episode depressed patients were randomly divided into observation group and control group,each of 30 cases. Observation group was given shuganjieyu capsule combined with paroxetine,and the control group was treated with paroxetine. HAMD scores,clinical curative effect and side effects at 2th week,4th week,8th week after the treatment between the two group were compared. Results Before the treatment,the difference of HAMD scores between the two groups was not statistically significant( P > 0. 05). After treatment,the HAMD in observation group scores began to decline in the first two weeks,HAMD score in the control group began to decrease in the first four weeks. The HAMD score in two groups during 2,4,8 weeks was statistically significant difference( P < 0. 05). The recovery rate and effective rate of observation group at 4th week,8th week after the treatment were higher than that of control group,the differences were statistically significant( P < 0. 05). There were not significant differences of side effects between two groups( P > 0. 05). Conclusion Shuganjieyu capsule combined with paroxetine in treatment of first-episode depression is more effectively than paroxetine used only,and has a high clinic recovery rate and few side effects.